ENLIVEN THERAPEUTICS INCORPORATED (ELVN)

The stock has a 50-day moving average of $46.75 and a 200 day moving average of $38.48. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $55.82. The firm has a market cap of $3.34 billion, a P/E ratio of -32.82 and a beta of 0.24. Enliven Therapeutics (NASDAQ:ELVN – Get…

Bank of America Corp DE lifted its stake in Elevance Health, Inc. (NYSE:ELV – Free Report) by 23.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,718,766 shares of the company’s stock after buying an ...

Elevance Health (NYSE:ELV – Get Free Report) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 27.000- for the period, compared to the consensus EPS estimate of 26.890. The company issued revenue guidance of -. Analyst Upgrades and ...

Investment management company Vulcan Value Partners recently released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. Vulcan Value Partners prioritizes long-term returns and lower risk over short-term performance. In the quarter, the Large Cap Composite ...

Q2 Results Ignite Debate: Social media users analyzed Elevance Health's second-quarter earnings, observing a beat on adjusted EPS and a raised full-year outlook that failed to prevent a post-release stock decline. Observers pointed to persistent pressure from thin Medicare Advantage margins ...